AXLA — Axcella Health Share Price
- $1.18m
- -$7.70m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | -1370.17% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Axcella Health Inc. is a clinical-stage biotechnology company. The Company is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.
Directors
- David Epstein CHM (59)
- William Hinshaw PRE (52)
- Robert Crane CFO (62)
- Alison Schecter CEX (57)
- Shreeram Aradhye EVP (58)
- Paul Fehlner SVP (57)
- Margaret Koziel SVP
- William Baird IND (49)
- Gregory Behar IND (52)
- Stephen Hoge IND
- Gary Pisano IND (59)
- Cristina Rondinone IND (60)
- Catherine Sohn IND (68)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- August 27th, 2008
- Public Since
- May 9th, 2019
- No. of Shareholders
- 28
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 2,947,661
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 840 Memorial Dr, CAMBRIDGE, 02139-3789
- Web
- https://axcellatx.com/
- Phone
- +1 6178680949
- Auditors
- Deloitte & Touche LLP
Upcoming Events for AXLA
Q1 2024 Axcella Health Inc Earnings Release
Similar to AXLA
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 18:03 UTC, shares in Axcella Health are trading at $0.40. This share price information is delayed by 15 minutes.
Shares in Axcella Health last closed at $0.40 and the price had moved by -95.14% over the past 365 days. In terms of relative price strength the Axcella Health share price has underperformed the S&P500 Index by -95.93% over the past year.
The overall consensus recommendation for Axcella Health is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Axcella Health does not currently pay a dividend.
Axcella Health does not currently pay a dividend.
Axcella Health does not currently pay a dividend.
To buy shares in Axcella Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.40, shares in Axcella Health had a market capitalisation of $1.18m.
Here are the trading details for Axcella Health:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AXLA
Based on an overall assessment of its quality, value and momentum Axcella Health is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Axcella Health is $10.87. That is 2611.4% above the last closing price of $0.40.
Analysts covering Axcella Health currently have a consensus Earnings Per Share (EPS) forecast of -$5.00 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Axcella Health. Over the past six months, its share price has underperformed the S&P500 Index by -93.09%.
As of the last closing price of $0.40, shares in Axcella Health were trading -94.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Axcella Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Axcella Health's management team is headed by:
- David Epstein - CHM
- William Hinshaw - PRE
- Robert Crane - CFO
- Alison Schecter - CEX
- Shreeram Aradhye - EVP
- Paul Fehlner - SVP
- Margaret Koziel - SVP
- William Baird - IND
- Gregory Behar - IND
- Stephen Hoge - IND
- Gary Pisano - IND
- Cristina Rondinone - IND
- Catherine Sohn - IND